louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04794816: What Women Want: Real Time Results During Screening Mammography in the Era of Patient-Experience Driven Care
Official title: What Women Want: Real Time Results for Screening Mammography in the Era of Patient-Experience Driven Care
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Breast Carcinoma
Lead sponsor: M.D. Anderson Cancer Center
Sponsor class: OTHER
First posted: 2021-03-12
Enrollment: 1000
Sex: FEMALE
Minimum age (years): 30
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients who are scheduled for a screening mammogram at one of three MD Anderson Breast Imaging Houston Area Locations (League City, Diagnostic Imaging (DI)-West Houston and The Woodlands) between December 15, 2020 and March 31, 2022.

Brief summary: This study explores why patients may want to receive real-time imaging results during a screening mammogram appointment at an MD Anderson breast imaging center. Real-time imaging results means women receive the results of the mammogram right away during the same clinic visit. Information from this study may help researchers better understand patient preferences to enhance patient-experience driven care.

Detailed description: PRIMARY OBJECTIVE:

I. To identify factors that may influence a patient's desire to receive real-time imaging results during their screening mammogram appointment at a breast center.

OUTLINE:

Participants complete an online questionnaire over 5 minutes regarding information on patient demographics and preferences for receiving real-time appointment imaging results.

Eligibility criteria: Inclusion Criteria:

* All female patients scheduled for a screening mammogram at one of our three MD Anderson Cancer Center (MDACC) Breast Imaging Houston Area Location centers
* Patient \>= 30 years of age
* Able to complete an electronic informed consent for the study

Exclusion Criteria:

* Patients not scheduled for a screening mammogram at one of the three imaging facilities

Primary outcomes:
measure: Factors that may influence a patient's desire to receive real-time imaging results during their screening mammogram appointment at a breast center
timeFrame: Up to study completion (estimated 2 years)
Secondary outcomes:
Other outcomes:
Locations:
city: Houston
country: United States
facility: M D Anderson Cancer Center
state: Texas
Study officials:
affiliation: M.D. Anderson Cancer Center
name: Megan J Kalambo, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00192816: Pain Perception in Alzheimer's Disease
Official title: Pain Perception in Alzheimer's Disease
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Dementia Alzheimer Type
Lead sponsor: Rambam Health Care Campus
Sponsor class: OTHER
First posted: 2005-09-19
Enrollment: 60
Sex: ALL
Minimum age (years): 55
Maximum age (years): 95
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: DEFINED_POPULATION
Time perspective: OTHER

Brief summary: The purpose of this study is to determine response to pain in Alzheimer's disease.We plan to study the effect of diffuse noxious inhibitory controls(counterirritation phenomenon)and the autonomic nervous system reaction(reflected by the heart rate) in Alzheimer's disease. The study's hypothesis is that pain perception and autonomic nervous system reaction are altered in Alzheimer's disease.


Eligibility criteria: Inclusion Criteria:

- Clinical diagnosis of Alzheimer's disease Must be able to understand a simple pain scale

Exclusion Criteria:

Neuropathy Psychotropic drugs use -

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Haifa
country: Israel
facility: Neurocognitive unit,Neurophysiology laborator Rambam Health Care Campus
Study officials:
affiliation: Rambam Health Care Campus
name: Judith Aharon-Peretz
role: STUDY_DIRECTOR
References:
Clinical trial NCT04313816: Difference Between Patient Vaccine Hesitancy and Perception by Their Family Physician of Their Vaccine Hesitancy
Official title: Difference Between Patient Vaccine Hesitancy and Perception by Their Family Physician of Their Vaccine Hesitancy
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Vaccine Hesitancy
Lead sponsor: University Hospital, Grenoble
Sponsor class: OTHER
First posted: 2020-03-18
Enrollment: 400
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients visiting their family physician in one participating medical practice

Brief summary: The investigators will ask to a patient and his/her family physician to complete in parallel a brief questionnaire at the beginning of the consultation:

* for the patient: self-evaluation of his/her vaccine hesitancy (with a 0-100 scale)
* for the physician: evaluation of this patient vaccine hesitancy (on the same 0-100 scale) Each of these 2 questionnaires should be filled blindly from the other.

Detailed description: The investigators will ask to a patient and his/her family physician to complete in parallel a brief questionnaire at the beginning of the consultation:

* for the patient: self-evaluation of his/her vaccine hesitancy (with a 0-100 scale)
* for the physician: evaluation of this patient vaccine hesitancy (on the same 0-100 scale) Each of these 2 questionnaires should be filled blindly from the other.

The investigators will recruit 400 to 500 patients in 20 medical practices of general practioners.

Eligibility criteria: Inclusion Criteria:

* visiting the family physician
* accepting the study after information

Exclusion Criteria:

* none apart from the reverse of inclusion criteria

Primary outcomes:
measure: difference between patient's vaccine hesitancy and perception by his/her family physician of his/her vaccine hesitancy.
timeFrame: one day
Secondary outcomes:
Other outcomes:
Locations:
city: Grenoble
country: France
facility: EPAULARD
Study officials:
References:
Clinical trial NCT03825016: Lidocaine Infusion in Hystroscopy
Official title: Lidocaine Infusion Versus Oral Diclofenac During Outpatient Hystroscopy: A Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Pain
Lead sponsor: Ain Shams University
Sponsor class: OTHER
First posted: 2019-01-31
Enrollment: 44
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Lidocaine infusion in hystroscopic media versus oral diclofenac


Eligibility criteria: Inclusion Criteria:

* Age 18-35 years
* BMI 18.5-30 kg/m2
* Diagnostic hystroscope

Exclusion Criteria:

* Previous cervical surgery
* Cervical stenosis
* PID
* allergy to NSAID
* Gastritis or peptic ulcer

Primary outcomes:
measure: Degree of pain "measured by visual analogue scale"
timeFrame: 1 hour
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Ain Shams University Maternity Hospital
Study officials:
References:
Clinical trial NCT06933316: The Effect of Family-Integrated Care Model on Infant and Toddler Health Promotion
Official title: The Effect of Family-Integrated Care Model on Infant and Toddler Health Promotion
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Family Caregiving
Infant Health
Growth
Nutrition
Cognition
Lead sponsor: Nanchong Maternal and Child Health and Family Planning Service Center
Sponsor class: OTHER
First posted: 2025-04-18
Enrollment: 158
Sex: ALL
Minimum age (years): 6
Maximum age (years): 18
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: The FIC model effectively promotes infant growth, improves nutrition, reduces disease risk, and supports early cognitive and psychological development while enhancing parental caregiving skills, demonstrating strong clinical value.

Detailed description: This study explored the effects of the family-integrated care (FIC) model on growth, nutrition, disease incidence, and early cognitive and psychological development in infants aged 6-18 months. A total of 158 full-term infants were randomly assigned to an intervention group (n=79) or a control group (n=79). The control group received routine health guidance, while the intervention group received additional FIC-based care, including individualized health plans, education, daily care guidance, dietary recommendations, micronutrient supplementation, early intervention, growth monitoring, and vaccination support. Outcomes assessed at baseline and six months post-intervention included growth indices (weight, height, head circumference), nutritional markers (hemoglobin, vitamin D), disease incidence (respiratory infections, gastrointestinal dysfunction, eczema), and Bayley Scales of Infant Development scores. Parental adherence, satisfaction, and caregiving competency were also evaluated.

Eligibility criteria: Inclusion Criteria:

1. Infants born in our hospital who undergo regular check-ups in the pediatric healthcare department.
2. Age between 6 and 18 months.
3. Complete and comprehensive clinical data.
4. Full-term birth.
5. Families voluntarily participate and sign informed consent.
6. Parents are in good health and have time to accompany their children daily.

Exclusion Criteria:

1. Congenital diseases.
2. Infectious diseases.
3. Familial hereditary diseases.
4. Abnormal conditions during pregnancy or perinatal period.
5. Missing clinical data.
6. No willingness to participate in this study.
7. Abnormal physical or intellectual development of the infant.
8. Intellectual disabilities of the guardians. -

Primary outcomes:
measure: The Effect of Family-Integrated Care Model on Infant and Toddler Health Promotion
timeFrame: 5 months
Secondary outcomes:
Other outcomes:
Locations:
city: Nanchong
country: China
facility: Nanchong Maternal and Child Health and Family Planning Service Center
Study officials:
References:
Clinical trial NCT05925816: Guided Feedback in an Online Game Impacts Decision Making
Official title: Understanding Decision Making Using a Text-based Game
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Depressive Symptoms
Keywords: depressive symptoms
Lead sponsor: Bard College
Sponsor class: OTHER
Collaborators: name: University of Texas at Austin
First posted: 2023-06-29
Enrollment: 350
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: OTHER

Brief summary: The purpose of the study is to evaluate the use of a text-based game as a way to understand decision making and knowledge related to anxiety, stress, and mood states like depression or loneliness. The investigators are interested in identifying whether participants who are given feedback before and during the game will report changes in behavior or depressive symptoms over the course of a one-week period. This is a follow-up to the published study from the researchers.


Eligibility criteria: Inclusion Criteria:

* 18+ age
* Eligible to participate in online research
* Able to read and respond in English

Exclusion Criteria:

* None

Primary outcomes:
measure: patient health questionnaire (PHQ; 8 items)
timeFrame: baseline (T0) - before intervention
measure: patient health questionnaire (PHQ; 8 items)
timeFrame: one week following intervention (T1)
measure: Behavior in study-specific game
timeFrame: Completed at baseline (T0)
Secondary outcomes:
measure: Generalized Anxiety Disorder 7 (GAD-7)
timeFrame: Baseline (T0) before intervention
measure: Generalized Anxiety Disorder 7 (GAD-7)
timeFrame: one-week follow-up (T1)
Other outcomes:
Locations:
city: Annandale-on-Hudson
country: United States
facility: Bard College
state: New York
Study officials:
References:
Clinical trial NCT04211116: Central Venous Catheters in Pediatric Anesthesia and Intensive Care
Official title: Central Venous Catheters in Pediatric Anesthesia and Intensive Care: Prospective Observational Trial
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Central Line
Keywords: Central line
Pediatric patient
Insertion
Cannulation
Lead sponsor: Brno University Hospital
Sponsor class: OTHER
First posted: 2019-12-26
Enrollment: 107
Sex: ALL
Maximum age (years): 19
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Pediatric patients

Brief summary: Securing the intravenous line is one of the fundamental interventions in paediatric anaesthesia and intensive care. Central venous catheters (CVC) are indicated for long-term stay in intensive care unit (ICU), in case of circulatory instability and the need for vasopressor therapy, for hypertonic solutions administration and parenteral nutrition. The dominant method of CVC insertions is the Seldingers´ method (over the wire) and ultrasound real-time navigation in recommended. Ultrasound-guided (USG) CVC insertion however requires experience personnel and relevant training.This could be the main reason, that CVC the real-time ultrasound navigation is still not adequately implemented into the clinical practice.

Detailed description: After Ethics committee approval, patients indicated for CVC insertions will be included. Based on the observational design of the trial, the method of insertion (Real-time ultrasound navigation versus anatomical-based CVC insertion) will be based on operators´ decision.The indication for CVC insertion, primary planned site of insertion, USG implementation, site of actual CVC cannulation and associated complications will be recorded. The primary aim of the study was to compare the effectivity of Real-time ultrasound navigation versus anatomical-based CVC insertion in paediatric patients and the 1st percutaneous puncture success rate. The secondary aims will be the incidence of associated complications and the time form first percutaneous puncture, to definitely securing the CVC in place. The primary hypothesis is that the Ultrasound-guided CVC insertion is superior, with the higher overall success, higher first attempt success rate and with lower incidence of associated complications.

Eligibility criteria: Inclusion Criteria:

* Pediatric patients within the age limit indicated for CVC insertion

Exclusion Criteria:

* Outside the age limit

Primary outcomes:
measure: Overall success and first attempt success rate
timeFrame: During CVC insertion
Secondary outcomes:
measure: Incidence of complications
timeFrame: 24 hours from CVC insertion
measure: Time of insertion
timeFrame: During CVC insertion
Other outcomes:
Locations:
city: Brno
country: Czechia
facility: University Hospital Brno
state: State
Study officials:
References:
Clinical trial NCT06435624: Effectiveness of Intelligent Rehabilitation Robot Training System Combined With Repetitive Facilitative Exercise on Upper Limb Motor Function After Stroke: a Randomized Control Trial.
Official title: Effectiveness of Intelligent Rehabilitation Robot Training System Combined With Repetitive Facilitative Exercise on Upper Limb Motor Function After Stroke: a Randomized Control Trial.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Stroke
Lead sponsor: Nanjing Mingzhou Rehabilitation Hospital
Sponsor class: OTHER
First posted: 2024-05-30
Enrollment: 81
Sex: ALL
Minimum age (years): 18
Maximum age (years): 74
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The goal of this clinical trial is to learn if intelligent rehabilitation robot training system combined with repetitive facilitative exercise (RFE) work to treat stroke in adults. The main questions it aims to answer are:

Does drug intelligent rehabilitation robot training system combined with RFE improve the upper limb motor function of participants? Can the combination of intelligent rehabilitation robot training system and RFE achieve better effects?

Researchers will compare 3 groups (RFE, intelligent rehabilitation robot training system under RFE, and conventional therapy) to see if intelligent rehabilitation robot training system and RFE works to treat stroke.

Participants will:

Receive treatment for 4 weeks Receive scale and instrument testing before and after treatment


Eligibility criteria: Inclusion Criteria:

* patients (18 to 74 years old) who suffered a first or second unilateral stroke
* chronic stroke (over 6 months from the onset)
* obvious upper limb movement disorders (FMA-UE scores from 25 to 42)
* ability to understand and follow simple directions

Exclusion Criteria:

* pregnant or lactating
* upper extremity contracture, pain, or trauma
* perceptual, apraxic, or cognitive deficits that lead to inability to follow verbal instructions
* unable to maintain sitting posture
* cerebellar lesion
* clinically unstable medical disorders
* inability to provide informed consent

Primary outcomes:
measure: Fugl-Meyer Assessment for Upper Extremity (FMA-UE)
timeFrame: From enrollment to the end of treatment at 4 weeks
measure: Active Participation Proportion
timeFrame: From enrollment to the end of treatment at 4 weeks
measure: Trajectory Deviation
timeFrame: From enrollment to the end of treatment at 4 weeks
measure: Trajectory Tracking Error
timeFrame: From enrollment to the end of treatment at 4 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Nanjing
country: China
facility: Nanjing Mingzhou Rehabilitation Hospital
state: Jiangsu
Study officials:
References:
Clinical trial NCT03458624: Long-term Observational Study to Evalution the Safety and Efficacy of FURESTEM-AD Inj.
Official title: Observational Study to Evaluate the Safety and Efficacy of FURESTEM-AD Inj. in Moderate to Severe Atopic Dermatitis Patients Who Participated in Phase 1/2a Clinical Trial of FURESTEM-AD Lnj.
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Atopic Dermatitis
Keywords: FURESTEM-AD Inj.
Stem cells
Lead sponsor: Kang Stem Biotech Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2018-03-08
Enrollment: 14
Sex: ALL
Minimum age (years): 19
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Subjects participating in this observational study originally participated in study FURESTEM-AD Inj. \[NCT01927705\]

Brief summary: Observational Study to Assess the Safety and Efficacy of FURESTEM-AD lnj. In moderate to Atopic Dermatitis

Detailed description: This is a observational study, single center, open label, study of safety and Efficacy of FURESTEM-AD Inj. in subjects with moderate to severe Atopic Dermatitis.

Eligibility criteria: Inclusion Criteria:

* Subjects participating in this observational study originally participated in study FURESTEM-RA Inj.\[NCT02221258\]
* Subject who understands and voluntarily sign an informed consent form

Exclusion Criteria:

* In case follow-up is not possible from end of clinical trial Phase 1/2a to end of this study period

Primary outcomes:
measure: Evaluate the number of adverse events Safety of FURESTEM-AD Inj.
timeFrame: 3 years
Secondary outcomes:
measure: Percentage of patients who decreased more than 50% in SCORAD(SCORing of Atopic Dermatitis) INDEX compared to Phase 2a clinical trial baseline
timeFrame: 3 years
measure: Variation of SCORAD Total Score as contrasted with Phase 2a clinical trial baseline value or Phase 2a clinical trial closing value
timeFrame: 3 years
measure: Percentage of subjects whose IGA(Investigator's Global Assessment) evaluation results were reduced to zero or one point
timeFrame: 3 years
measure: Variation of serum Total IgE as contrasted with Phase 2a clinical trial baseline value or Phase 2a clinical trial closing value
timeFrame: 3 years
measure: Variation of EASI(Eczema area and severity index) as contrasted with Phase 2a clinical trial baseline value or Phase 2a clinical trial closing value
timeFrame: 3 years
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Seoul ST. Mary's Hospital
Study officials:
affiliation: Seoul St. Mary's Hospital
name: Tae-Yun Kim
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06001424: Effect of Life Kinetik Training on Lower Limb Coordination in Ataxic Patients
Official title: Effect of Life Kinetik Training on Lower Limb Coordination in Ataxic Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Multiple Sclerosis
Ataxia
Keywords: Multiple Sclerosis
ataxia
coordination
life kinetic exercises
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2023-08-21
Enrollment: 30
Sex: ALL
Minimum age (years): 20
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: randomized controlled trail
Primary purpose: TREATMENT

Brief summary: Coordination is essential for the performance of most daily motor activities. Coordination problems are common in MS patients. One of the most commonly reported symptoms is dysmetria (limb ataxia). Ataxia is thought to occur in about 80% of MS patients. It leads to limitations in daily life activities. Aim of Study: to investigate the effect of life kinetik training on lower limb coordination in MS patients with ataxia.

Detailed description: Methods: Thirty remitting relapsing Multiple Sclerosis (RRMS) patients from both sexes with ataxic symptoms, will be recruited from multiple sclerosis specialized clinic in the Neurology department, Faculty of Medicine, Cairo University with EDSS score will be ranged from 2 to 4 and SARA score will be ranged from 1 to 10. Lower Extremity Motor Coordination Test (LEMOCOT) will be used to assess lower limb motor coordination. They will be randomly assigned into two equal groups; control group (GI) will receive selected physical therapy program and study group (GII) will receive same program of (GI) in addition to life kinetik training.

Eligibility criteria: Inclusion Criteria:

* MS from both sexes
* Patients' age will be ranged from 20 to 45 years
* Expanded disability scale (EDSS) score ranging from "two" to "four"

Exclusion Criteria:

* Patients with Ataxia caused by other cause rather than MS
* Patients with other neurological disease or orthopedic deformities may affect movement
* Patients with cardiovascular and pulmonary diseases that make exercise unsafe
* Patients with cognitive impairment or psychiatric disorders

Primary outcomes:
measure: Lower Extremity Motor Coordination Test (LEMOCOT)
timeFrame: at baseline
measure: Lower Extremity Motor Coordination Test (LEMOCOT)
timeFrame: post intervention (after one month)
Secondary outcomes:
measure: Four Square Step Test (FSST)
timeFrame: at baseline
measure: Four Square Step Test (FSST)
timeFrame: post intervention (after one month)
Other outcomes:
Locations:
city: Giza
country: Egypt
facility: Faculty of Physical Therapy
Study officials:
affiliation: Professor of Physical therapy for Neurology
name: Moshera H Darwish, Prf. Dr
role: STUDY_DIRECTOR
References:
citation: Edwards EM, Fritz NE, Therrien AS. Cerebellar Dysfunction in Multiple Sclerosis: Considerations for Research and Rehabilitation Therapy. Neurorehabil Neural Repair. 2022 Feb;36(2):103-106. doi: 10.1177/15459683211065442. Epub 2021 Dec 21.